The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Eli Lilly shares weight loss drug market leadership with fellow big pharma player Novo Nordisk. They each commercialize two ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday.

The incidence of obesity and diabetes is rising in India, the world’s most populous country, which also ranks among the worst ...

Another experimental therapy from Eli Lilly also helped patients shed pounds with few side effects in a small study, impressing analysts. The drug, called eloralintide, is part of a class of drugs ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.